A plain-language care & cost guide Source desk
Check the product, then the claim.
What was actually studied? What did the FDA review? The useful answer starts with the exact product, not the broad word peptide.
Jump to a question
What does approval actually cover?
FDA, the Food and Drug Administration, reviews each medicine for particular uses.
In September 2026, semaglutide (Ozempic, Wegovy) has FDA approval, as does tirzepatide (Mounjaro, Zepbound); approval still depends on the named product and use.
For semaglutide (Wegovy), approved uses include weight loss and keeping weight off, with diet and activity changes, as of September 2026.
Blood-sugar management for adults with type 2 diabetes is an approved use of semaglutide (Ozempic) injection, as of September 2026.
Ask for the label for the medicine being offered. Ask which approved use matches your health problem. Say the medicine’s name and whether it is a shot, tablet or something else.
Source note AWhat changes when a drug is made to order?
The word compounded describes medicine that a pharmacist or doctor has made to order.
A compounded drug, as of September 2026, has no FDA approval or FDA check of quality, safety or whether it works before sale.
Compounding may fill a medical need that approved medicines cannot fill, under the rules in place as of September 2026.
Ask why a custom-made medicine is being proposed for you. Ask who makes it. Ask whether studies in people tested that same medicine for your health problem.
Source note BDoes the old shortage story still apply?
As of September 2026, FDA no longer lists injections of semaglutide or tirzepatide as being in shortage.
In September 2026, one pharmacy running out did not mean a medicine was on FDA’s national shortage list.
If a pharmacy offers a custom-made copy because of a shortage, ask which current rule allows it. Ask whether that exact medicine is on FDA’s national shortage list now.
Source note CWhat about a peptide mentioned online?
BPC-157 is a peptide name used in online treatment offers; it has no FDA-approved US medicine as of September 2026.
If someone offers it for your health problem, ask what benefit they claim and which study in people backs that claim.
For BPC-157, FDA says it lacks enough human safety information to know whether proposed uses would cause harm, as checked in September 2026.
Evidence means the information used to back a treatment claim, such as results from a study in people. Ask what medicine was studied and how people received it.
- Did the study involve people with my health problem?
- Was it the same medicine, given the same way, such as a shot or tablet?
- What other treatment, or no treatment, was it compared with?
- What unwanted problems did the researchers look for?
Notes behind these answers
- A
These FDA labels describe the named products and their approved uses. Ask the care professional to explain the part that matters for your goal.
FDA label: semaglutide (Wegovy)FDA label: semaglutide (Ozempic) injectionFDA label: tirzepatide (Mounjaro) - B
The FDA’s compounding explanation describes what the agency does and does not review for a custom-made drug.
FDA explanation of compounding - C
FDA explains that a medicine may still be hard to find locally after its national shortage ends.
FDA supply and copying updates - D
The FDA’s ingredient review explains where information from studies in people is missing.
FDA: concerns about proposed ingredients